Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Community-acquired Pneumonia
Interventions: Trimodulin, Placebo (human albumin 1%); Drug
Lead sponsor: Biotest; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 29
States / cities: Mobile, Alabama • Phoenix, Arizona • Fresno, California + 23 more

Conditions: Alzheimer Disease
Interventions: GV-971, Placebo; Drug
Lead sponsor: Green Valley (Shanghai) Pharmaceuticals Co., Ltd.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 2,046 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 67
States / cities: Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 57 more

Conditions: Hypertension
Interventions: valsartan; Drug
Lead sponsor: Novartis; Industry
Eligibility: 1 Year to 5 Years
Enrollment: 90 participants
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Pain, Postoperative
Interventions: PMI-150 (intranasal ketamine), Placebo; Drug
Lead sponsor: Hospira, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 16
States / cities: Birmingham, Alabama • Florence, Alabama • Sheffield, Alabama + 13 more

Conditions: Developmental Disability, Autism Spectrum Disorder, Down Syndrome, Cerebral Palsy
Interventions: Zumba High Tempo, Zumba Low Tempo; Behavioral
Lead sponsor: Auburn University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Alzheimer Disease, Early Onset
Interventions: AD-35 60mg group, Placebo group; Drug
Lead sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 10
States / cities: Sacramento, California • San Diego, California • Delray Beach, Florida + 7 more

Conditions: Psoriasis
Interventions: Apremilast (CC-10004), Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 35 more

Conditions: Parkinson's Disease
Interventions: Multiplex Sensitivity Encoding (MUSE); Device
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Angelman Syndrome, Nervous System Diseases
Interventions: Betaine, Creatine, Metafolin, Vitamin B12; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 1 Day to 5 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 4
States / cities: San Diego, California • Boston, Massachusetts • Greenwood, South Carolina + 1 more

Conditions: Otherwise Healthy Overweight or Obese
Interventions: PHP-303, Placebo; Drug · Other
Lead sponsor: pH Pharma; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Gastric Cancer, Gastroesophageal Junction Cancer
Interventions: AZD0901, Ramucirumab+ paclitaxel, Paclitaxel, Docetaxel, Irinotecan, TAS-102, Apatinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 26
States / cities: Mobile, Alabama • Tucson, Arizona • Duarte, California + 19 more

Conditions: Peri-Implantitis
Interventions: Minocycline HCl Microspheres; Drug
Lead sponsor: OraPharma; Industry
Eligibility: 21 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 10
States / cities: Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan + 7 more

Conditions: Acute Myeloid Leukemia
Interventions: BST-236; Drug
Lead sponsor: BioSight Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 11
States / cities: Augusta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 8 more

Conditions: Insertional Achilles Tendinopathy
Interventions: TAPESTRY Biointegrative Implant; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: Not listed
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Libertyville, Illinois • Tulsa, Oklahoma

Conditions: Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions: PN 200 tablets (500 mg naproxen and 20 mg omeprazole), Naproxen 500 mg tablets (PN 200 minus omeprazole); Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Pompano Beach, Florida

Conditions: Partial Obstruction of Systemic to Pulmonary Artery Shunt, Complete Obstruction of Systemic to Pulmonary Artery Shunt
Interventions: Cangrelor; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 1 Day to 28 Days
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: New York, New York • Pittsburgh, Pennsylvania

Conditions: Alzheimer's Disease
Interventions: NGP 555; Drug
Lead sponsor: NeuroGenetic Pharmaceuticals Inc; Industry
Eligibility: 40 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Cypress, California

Conditions: Coronary Artery Disease
Interventions: Ticagrelor Tablets, Clopidogrel (over encapsulated) capsule, Aspirin Tablets; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 8
States / cities: Baton Rouge, Louisiana • Baltimore, Maryland • Towson, Maryland + 5 more

Conditions: Acute Myeloid Leukemia
Interventions: IMGN779; Drug
Lead sponsor: ImmunoGen, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 7
States / cities: Birmingham, Alabama • Boston, Massachusetts • Albuquerque, New Mexico + 4 more

Conditions: Epilepsy
Interventions: diazepam nasal spray; Drug
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 33
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 26 more

Conditions: Non-Hodgkin's Lymphoma
Interventions: SDX-105; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 13
States / cities: Birmingham, Alabama • Palm Springs, California • Vista, California + 10 more

Conditions: Thrombocytopenia, Hematologic Diseases, Bone Marrow Aplasia
Interventions: Thrombosomes; Biological
Lead sponsor: Cellphire Therapeutics, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Duarte, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 3 more

Conditions: Dry Eye
Interventions: Carboxymethylcellulose sodium and Glycerin; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Warrensburg, Missouri

Conditions: Multiple Sclerosis, Spinal Cord Injury, Chronic Pain, Other and Unspecified Amputation Stump Complications, Muscular Dystrophies, Low Back Pain
Interventions: Pain Self-Management Intervention #1, Pain Self-Management Intervention #2, Pain Self-Management Intervention #3, Pain Self-Management Intervention #4; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease

A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have Hypertension

Safety and Efficacy of Repeated Doses of PMI-150 (Intranasal Ketamine) in Acute Post-operative Pain Following Orthopedic Surgery

The Effects of Virtual Zumba® in Individuals With Developmental Disabilities

Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

Motion Immune Magnetic Resonance Imaging (MRI)

Dietary Supplements for the Treatment of Angelman Syndrome

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese Subjects

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Arestin - Use in Subjects With Peri-Implantitis (With Subgingival Microbiological Evaluation)

Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy

Embody Insertional Achilles Tendinopathy

Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.

Cangrelor Neonatal PK/PD and Safety Study

Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose)

A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin

Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.

Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma

Thrombosomes® in Bleeding Thrombocytopenic Patients

A Multi-Center Randomized Study to Evaluate the Efficacy and Safety of an Investigational Lubricant Eye Drop

Power Over Pain (POP) Study